Dr. Raez on the KEYNOTE-407 Trial in Squamous Cell Carcinoma of the Lung

08 Oct, 2019 ,

Dr.Raez discusses the impact of the KEYNOTE-407 trial in squamous non–small cell lung cancer (NSCLC). For many years, squamous NSCLC has been behind in drug development because agents, such as pemetrexed and bevacizumab (Avastin), did not have indications for squamous cell carcinoma, explains Raez.